Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
National Institute Of Biological Sciences Beijing currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution suggests a range of biological research topics currently under review, requiring the institute to navigate multiple technical standards simultaneously. The use of 2 different art units indicates that the institute's current patent activity spans different specialized fields within the life sciences. The presence of 2 pending office actions shows an active phase of prosecution for the institute's research.
DHAR, MATASHA is identified as the busiest examiner, holding 1 busiest examiner pending action. This examiner handles 1 of the 2 active actions in the portfolio. With 2 actions split between 2 examiners in 2 different art units, the institute must manage multiple examination styles. Practitioners should be prepared for varied feedback across these 2 pending actions, as each examiner will apply the standards of their respective art unit. The resolution of these actions will provide a broader view of the institute's current patenting success across its Biotechnology & Pharmaceuticals research areas. Managing these distinct examiner relationships is key for the institute.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| DHAR, MATASHA | 1 | 43.3% | +45.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | VIJAYARAGHAVAN, JAGAMYA NMN | 25d overdue |
| 17614737 | ANIMAL MODEL OF IDIOPATHIC PULMONARY FIBROSIS, ITS CONSTRUCTION METHOD AND USE | DHAR, MATASHA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | VIJAYARAGHAVAN, JAGAMYA NMN | 25d overdue |
| 17614737 | ANIMAL MODEL OF IDIOPATHIC PULMONARY FIBROSIS, ITS CONSTRUCTION METHOD AND USE | DHAR, MATASHA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§112Other | Non-Final OA | 25d overdue | Pending | Nov 29, 2021 |
| 17614737 | ANIMAL MODEL OF IDIOPATHIC PULMONARY FIBROSIS, ITS CONSTRUCTION METHOD AND USE | DHAR, MATASHA | 1632 | §103§112 | Non-Final OA | — | Pending | Nov 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial